News Image

Delving into NASDAQ:AMPH's Growth Prospects.

By Mill Chart

Last update: Feb 28, 2024

In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our CANSLIM growth screen, which makes it worth to investigate a bit more.

Some of the canslim metrics of NASDAQ:AMPH highlighted

  • With a favorable trend in its quarter-to-quarter (Q2Q) earnings per share (EPS), AMPHASTAR PHARMACEUTICALS IN highlights its ability to generate increasing profitability, showcasing a 203.0% growth.
  • With consistent quarter-to-quarter (Q2Q) revenue growth of 50.37%, AMPHASTAR PHARMACEUTICALS IN exemplifies its ability to generate increased sales and revenue streams. This growth signifies the company's strong business performance and its potential for continued growth.
  • AMPHASTAR PHARMACEUTICALS IN has experienced 77.88% growth in EPS over a 3-year period, demonstrating its ability to generate sustained and positive earnings momentum.
  • AMPHASTAR PHARMACEUTICALS IN has a healthy Return on Equity(ROE) of 22.72%. This demonstrates the company's efficient utilization of capital and indicates its commitment to driving profitability.
  • AMPHASTAR PHARMACEUTICALS IN has exhibited strong Relative Strength(RS) in recent periods, with a current 85.97 rating. This indicates the stock's ability to outperform the broader market and reflects its competitive position. AMPHASTAR PHARMACEUTICALS IN shows promising potential for continued price momentum.
  • AMPHASTAR PHARMACEUTICALS IN exhibits a favorable Debt-to-Equity ratio at 1.07. This highlights the company's ability to limit excessive debt levels and maintain a strong equity base, demonstrating its financial stability and risk management practices.
  • With 69.78% of the total shares held by institutional investors, AMPHASTAR PHARMACEUTICALS IN showcases a healthy distribution of ownership. This suggests a mix of institutional and retail investors, fostering a dynamic market for the stock.

Zooming in on the technicals.

ChartMill assigns a Technical Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple technical indicators and properties.

Overall AMPH gets a technical rating of 8 out of 10. This is due to a consistent overall performance, although we see some doubts in the very recent evolution. In the medium time frame things are still looking good.

  • The long term trend is positive and the short term trend is neutral. The long term trend gets the benefit of the doubt for now.
  • Looking at the yearly performance, AMPH did better than 85% of all other stocks. On top of that, AMPH also shows a nice and consistent pattern of rising prices.
  • AMPH is part of the Pharmaceuticals industry. There are 202 other stocks in this industry. AMPH outperforms 73% of them.
  • In the last month AMPH has a been trading in the 51.08 - 56.45 range, which is quite wide. It is currently trading near the high of this range.
  • AMPH is currently trading in the middle of its 52 week range. The S&P500 Index however is currently trading near new highs, so AMPH is lagging the market.

Check the latest full technical report of AMPH for a complete technical analysis.

A complete fundamental analysis of NASDAQ:AMPH

Every day ChartMill assigns a Fundamental Rating to every stock. The score ranges from 0 to 10 and is determined by evaluating multiple fundamental indicators and properties.

We assign a fundamental rating of 7 out of 10 to AMPH. AMPH was compared to 202 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make AMPH suitable for value and growth investing!

For an up to date full fundamental analysis you can check the fundamental report of AMPH

Our CANSLIM screen will find you more ideas suited for growth investing.


This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.



NASDAQ:AMPH (4/24/2024, 7:00:00 PM)

After market: 41 0 (0%)


+0.09 (+0.22%)


News Image6 days ago - Market News VideoOversold Conditions For Amphastar Pharmaceuticals (AMPH)
News Image12 days ago - Market News VideoCommit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
News Image2 months ago - Market News VideoAmphastar Pharmaceuticals Becomes Oversold (AMPH)
News Image2 months ago - Market News VideoAmphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA
News Image2 months ago - Seeking AlphaAmphastar Pharmaceuticals Non-GAAP EPS of $0.88 misses by $0.03, revenue of $178.1M beats by $4.77M (NASDAQ:AMPH)

Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...

News Image2 months ago - Investor's Business DailyCRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image3 months ago - Market News VideoAMPH Crosses Below Key Moving Average Level
News Image3 months ago - InvestorPlace3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

News Image3 months ago - Investor's Business DailyAxsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

AMPH Links
Follow us for more